Cutler Group’s NovoCure NVCR Stock Holding History

Cutler Group’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5,400	Closed	-$49K	–	4164
2023 Q2	$49K	Sell	5,400 -800	-13%	-$49.7K	0.01%	1297
2023 Q1	$173K	Buy	6,200 +2,500	+68%	+$200K	0.02%	751
2022 Q4	$277K	Sell	3,700 -200	-5%	-$15K	0.02%	646
2022 Q3	$251K	Buy	3,900 +500	+15%	+$39K	0.02%	846
2022 Q2	$277K	Sell	3,400 -4,200	-55%	-$316K	0.02%	818
2022 Q1	$275K	Buy	7,600 +2,800	+58%	+$206K	0.01%	1000
2021 Q4	$350K	Hold	4,800	–	–	0.01%	937
2021 Q3	$198K	Buy	4,800 +3,800	+380%	+$575K	0.01%	1370
2021 Q2	$4K	Buy	+1,000	New	+$195K	﹤0.01%	4614
2017 Q4	–	Sell	-1,900	Closed	-$1K	–	5591
2017 Q3	$1K	Buy	+1,900	New	+$37.3K	﹤0.01%	5486
2017 Q1	–	Sell	-2,900	Closed	-$6K	–	6947
2016 Q4	$6K	Sell	2,900 -41,100	-93%	-$331K	﹤0.01%	4773
2016 Q3	$14K	Buy	44,000 +32,100	+270%	+$293K	﹤0.01%	3809
2016 Q2	$45K	Buy	11,900 +10,300	+644%	+$129K	﹤0.01%	2464
2016 Q1	$26K	Sell	1,600 -2,300	-59%	-$33K	﹤0.01%	3011
2015 Q4	$23K	Buy	+3,900	New	+$93.2K	﹤0.01%	3277

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cutler Group's NVCR Position: Q1 2024 in Review

Cutler Group opened a new position in NovoCure (NVCR) in Q1 2024: 869 shares worth $13K. The stake represents ﹤0.01% of the portfolio and ranks #1188 among its holdings. This is a return to the name: Cutler Group previously reported a position in NVCR as recently as Q3 2023.

Cutler Group first reported a position in NVCR in Q4 2015 and has held it in 18 quarters since. The position peaked at $732K in Q4 2021. 237 funds tracked by Wall St. Rank hold NVCR as of Q1 2024.

Cutler Group held 869 shares of NovoCure worth $13K as of Q1 2024.
NovoCure was a new Cutler Group position in Q1 2024.
NovoCure made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1188 holding.
Cutler Group first reported a position in NovoCure in Q4 2015 and has held it in 18 quarters since.
Cutler Group's NovoCure position peaked at $732K in Q4 2021.
237 funds tracked by Wall St. Rank held NovoCure as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.